HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

AKESO

171.200

+8.2005.03%

Volume:11.49M

Turnover:1.93B

Market Cap:153.74B

PE:-259.22

High:173.200

Open:165.000

Low:161.400

Close:163.000

Loading ...

Overview Company News Filings

LIVE MARKETS-Chinese biotech licensing deals draw U.S. interest despite modest size, Macquarie says

Chinese Biotech Companies' Outlicensing Trend Will Likely Be Sustainable -- Market Talk

Akeso Inc. Receives Regulatory Approval from U.S. FDA, Australia's TGA, and China's NMPA to Begin Clinical Trials for First Bispecific ADC, AK146D1

HK Movers｜HK Innovative Drug Concept Stocks Rose. Biostar Up 15%; Akeso Up 11%; SKB Bio And Innovent Bio Up More Than 7%

Tiger Newspress

Akeso Inc. Conducted Annual and Extraordinary General Meetings

Cadonilimab Receives Regulatory Approval from China's NMPA for First-Line Treatment of Advanced Cervical Cancer, Reports Akeso Inc

TransThera Sciences Launches Up to HK$201 Million IPO in Hong Kong

MT Newswires Live

Akeso Inc. Receives NMPA Approval for Cadonilimab as First-Line Treatment for Cervical Cancer

Akeso Hits Snag with Less Favorable Clinical Trial Data for Lung Cancer Treatment; Shares Rise 7%

MT Newswires Live

Akeso Grants Share Options, Restricted Share Units

MT Newswires Live

Akeso Inc. Announces New Grant of Share Options and Restricted Share Units for Directors and Employees

Pfizer Is Jumping Into a Hot Cancer-Drug Race. It May Have Overpaid. -- Barrons.com

Nomura Downgrades Akeso to Neutral From Buy, Adjusts Price Target to HK$99.66 From HK$75.14

MT Newswires Live

Akeso Gets China Nod for Lung Cancer Drug Indication

MT Newswires Live

US FDA Approves Nasopharyngeal Carcinoma Drug

MT Newswires Live

BRIEF-Akeso Says FDA Approved Anniko (Penpulimab-Kcqx, Pd-1) In Two Indications

HK Movers | Biotech Stocks Jump With ImmuneOnco up 10%

Tiger Newspress

Akeso's Lung Cancer Drug Meets Primary Endpoints in China Phase 3 Trial; Shares Rise 5%

MT Newswires Live

HK Movers | Biotech Stocks Rally With Zai Lab up 8%

Tiger Newspress

Akeso's NDA for Plaque Psoriasis Drug Gets China Nod

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/09926/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09926","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09926\",,,,,undefined,":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"AKESO","latestPrice":171.2,"timestamp":1754467711006,"preClose":163,"halted":0,"volume":11491710,"delay":0,"floatShares":898000000,"shares":898000000,"eps":-0.6604449848352839,"marketStatus":"Not Yet Opened","change":8.2,"latestTime":"08-06 16:08:31","open":165,"high":173.2,"low":161.4,"amount":1926582894,"amplitude":0.072393,"askPrice":171.2,"askSize":8000,"bidPrice":171.1,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":-0.6604449848352839,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1754530200000},"marketStatusCode":0,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":163,"openAndCloseTimeList":[[1754443800000,1754452800000],[1754456400000,1754467200000]],"volumeRatio":0.9293508453210018,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09926\",,,,,undefined,":{"symbol":"09926","floatShares":898000000,"roa":"-4.16%","roe":"-8.89%","lyrEps":-0.660445,"volumeRatio":0.9293508453210018,"shares":898000000,"dividePrice":0,"high":173.2,"amplitude":0.072393,"preClose":163,"low":161.4,"week52Low":42.8,"pbRate":"20.65","psRate":"66.26","week52High":173.2,"institutionHeld":0,"latestPrice":171.2,"committee":-0.333333,"eps":-0.6604449848352839,"divideRate":0,"volume":11491710,"delay":0,"ttmEps":-0.6604449848352839,"open":165,"prevYearClose":60.7,"prevWeekClose":156.3,"prevMonthClose":154.6,"prevQuarterClose":91.95,"fiveDayClose":152.8,"twentyDayClose":109.8,"sixtyDayClose":80.9},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09926\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548381910","title":"LIVE MARKETS-Chinese biotech licensing deals draw U.S. interest despite modest size, Macquarie says","url":"https://stock-news.laohu8.com/highlight/detail?id=2548381910","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548381910?lang=en_us&edition=fundamental","pubTime":"2025-07-04 01:18","pubTimestamp":1751563124,"startTime":"0","endTime":"0","summary":"LIVE MARKETS-Chinese biotech licensing deals draw U.S. interest despite modest size, Macquarie saysMain US indexes rally; Nasdaq ends up ~1%Tech leads S&P 500 sectors gainers; Materials end flatDollar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nL4N3T014S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BBT3K403.USD","LU1894683264.USD","LU0225771236.USD","LU0306806265.USD","LU1794554557.SGD","01801","BK7511","LU2328871848.SGD","SG9999002224.SGD","SG9999002232.USD","BK4550","BK4588","IE000M9KFDE8.USD","IE00BPRC5H50.USD","IE00B543WZ88.USD","BK4585","LU0058720904.USD","BK4599","LU0122379950.USD","BK1161","SG9999011175.SGD","IE00B19Z3B42.SGD","BK4533","LU0321505439.SGD","SG9999013999.USD","LU1066051498.USD","SG9999001176.SGD","LU1894683348.USD","03692","LU0170899867.USD","LU0306807586.USD","LU0417516571.SGD","SGXZ57979304.SGD","SG9999003800.SGD","BK1583","LU1023059063.AUD","BK1191","LU0321505868.SGD","LU2488822045.USD","LU0868494617.USD","LU1066053197.SGD","BK1574","IE00B19Z3581.USD","IE00BLSP4452.SGD","BK1589","LU1883839398.USD","IE0002270589.USD","09926","MQG.AU"],"gpt_icon":1},{"id":"2548087992","title":"Chinese Biotech Companies' Outlicensing Trend Will Likely Be Sustainable -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2548087992","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548087992?lang=en_us&edition=fundamental","pubTime":"2025-07-03 16:34","pubTimestamp":1751531640,"startTime":"0","endTime":"0","summary":"0834 GMT - China's biotech companies' outlicensing trend is sustainable, Jefferies analysts write in a note. The analysts are seeing overwhelming interest and potential incremental fund flows from global healthcare specialists, who are looking into China with the acceleration of biotech outlicensing, they say. Among the companies, Wuxi Biologics mentioned that the higher manufacturing cost in the U.S. will be shouldered by customers, they say. The company's single-asset turnover could reach between two and four times that of its global peers', Jefferies says. Investors are also interested in JD Health for its out-of-pocket branded drug business that could lead to stronger orders, they say. Jefferies's top picks for the sector are Wuxi Biologics, JD Health, Akeso, Duality Biotherapeutics, Hansoh Pharmaceutical and United Imaging. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0039217434.USD","SG9999002463.SGD","LU1794554557.SGD","BK1583","BK1247","IE00B0JY6N72.USD","LU0456846285.SGD","02269","LU0516423091.SGD","LU0043850808.USD","LU0516422952.EUR","SG9999002562.SGD","03692","BK1574","LU0140636845.USD","BK1591","LU1880383366.USD","86618","LU0348784397.USD","LU0979878070.USD","BK1571","BK1589","IE00B543WZ88.USD","LU0708995583.HKD","LU0307460666.USD","BK1191","06618","LU0181495838.USD","LU0348825331.USD","LU1688375341.USD","LU0320764599.SGD","LU0348735423.USD","09926","LU0456827905.SGD","LU1720050803.USD","LU0516422366.SGD","IE00B5MMRT66.SGD","LU0326950275.SGD","LU0051755006.USD","LU0359202008.SGD","LU0052750758.USD","IE00BPRC5H50.USD","LU0516423174.USD","BK1142","LU0823426308.USD","BK1521","LU2488822045.USD","LU0417516571.SGD","09606","LU0819121731.USD"],"gpt_icon":0},{"id":"2548820850","title":"Akeso Inc. Receives Regulatory Approval from U.S. FDA, Australia's TGA, and China's NMPA to Begin Clinical Trials for First Bispecific ADC, AK146D1","url":"https://stock-news.laohu8.com/highlight/detail?id=2548820850","media":"Reuters","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548820850?lang=en_us&edition=fundamental","pubTime":"2025-07-03 14:47","pubTimestamp":1751525226,"startTime":"0","endTime":"0","summary":"Akeso Inc. Receives Regulatory Approval from U.S. FDA, Australia's TGA, and China's NMPA to Begin Clinical Trials for First Bispecific ADC, AK146D1. Akeso Inc. has announced that its first bispecific Antibody-Drug Conjugate , AK146D1, has received regulatory approval to commence clinical trials from the U.S. Food and Drug Administration , Australia's Therapeutic Goods Administration , and China's National Medical Products Administration . This marks a significant milestone for Akeso, as AK146D1 targets both Trop2 and Nectin4, representing a key component of the company's \"IO+ADC\" 2.0 strategy aimed at advancing cancer therapies. The approval allows Akeso to proceed with its Phase Ia clinical trial, with the first patient already successfully enrolled.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nNDL968s4F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1794554557.SGD","09926","BK1574","LU0348783233.USD","LU0417516571.SGD","LU2488822045.USD","LU1720050803.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","IE00BPRC5H50.USD","BK1161","LU0348784397.USD"],"gpt_icon":0},{"id":"1109523465","title":"HK Movers｜HK Innovative Drug Concept Stocks Rose. Biostar Up 15%; Akeso Up 11%; SKB Bio And Innovent Bio Up More Than 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109523465","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109523465?lang=en_us&edition=fundamental","pubTime":"2025-07-03 11:00","pubTimestamp":1751511647,"startTime":"0","endTime":"0","summary":"HK Innovative Drug Concept Stocks Rose. Biostar up 15%; Akeso up 11%; SKB Bio and Innovent Bio up more than 7%; Zai Lab up 5%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759","06990","09995","09926","02137","06606","01801","02563","02269","09606","02359","06978","01672","09966","09688","03347","02268"],"gpt_icon":0},{"id":"2547015047","title":"Akeso Inc. Conducted Annual and Extraordinary General Meetings","url":"https://stock-news.laohu8.com/highlight/detail?id=2547015047","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547015047?lang=en_us&edition=fundamental","pubTime":"2025-06-30 23:47","pubTimestamp":1751298457,"startTime":"0","endTime":"0","summary":"Akeso Inc. held its Annual General Meeting  and Extraordinary General Meeting  on June 30, 2025. All the resolutions proposed at both meetings were approved by the shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief on June 30, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDL5BB1pQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","BK1161","LU0417516571.SGD","BK1574","LU2488822045.USD","IE00B5MMRT66.SGD","LU1794554557.SGD","LU0348783233.USD","LU1720050803.USD","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU0348784397.USD"],"gpt_icon":0},{"id":"2543610732","title":"Cadonilimab Receives Regulatory Approval from China's NMPA for First-Line Treatment of Advanced Cervical Cancer, Reports Akeso Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2543610732","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543610732?lang=en_us&edition=fundamental","pubTime":"2025-06-16 09:25","pubTimestamp":1750037143,"startTime":"0","endTime":"0","summary":"Cadonilimab Receives Regulatory Approval from China's NMPA for First-Line Treatment of Advanced Cervical Cancer, Reports Akeso Inc. Akeso Inc. has announced a significant regulatory approval for their innovative treatment, cadonilimab. The China National Medical Products Administration  has approved the use of cadonilimab as a first-line treatment for advanced, recurrent, or metastatic cervical cancer as of May 2025. This approval marks an important milestone for Akeso, as cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, has shown significant improvements in progression-free survival and overall survival in various patient subgroups. This development highlights the ongoing impact of cadonilimab in transforming the treatment standards for advanced cervical cancer and underscores its potential global health benefits for women.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDL83jy4r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cadonilimab Receives Regulatory Approval from China's NMPA for First-Line Treatment of Advanced Cervical Cancer, Reports Akeso Inc","news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B543WZ88.USD","LU0348784397.USD","LU0417516571.SGD","LU0348783233.USD","LU1794554557.SGD","LU2488822045.USD","IE00B5MMRT66.SGD","09926","BK1161","BK1574","LU1720050803.USD","IE00BPRC5H50.USD"],"gpt_icon":0},{"id":"2543579573","title":"TransThera Sciences Launches Up to HK$201 Million IPO in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2543579573","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543579573?lang=en_us&edition=fundamental","pubTime":"2025-06-13 11:06","pubTimestamp":1749783992,"startTime":"0","endTime":"0","summary":"TransThera Sciences  launched its initial public offering in Hong Kong that seeks to raise up to HK$200.9 million, according to a Friday Hong Kong bourse filing.The clinical-stage biopharmaceutical firm is offering as much as 15,281,000 shares at an indicative price of HK$13.15 each.TransThera secured five cornerstone investors, including Jiangbei Pharmaceutical, Akeso , Sinohsc Honest, Pharmablock Horizon, and Kelingan, which committed to subscribe for a combined HK$130.0 million worth of IPO shares, representing around 64.1% of the offering.The issuer expects to determine its offer price and disclose the allocations on June 20. It will then start trading on the Hong Kong bourse on June 23, according to a prospectus filing.Proceeds from the deal will primarily fund a multiregional Phase III trial of its core product Tinengotinib, with remaining funds allocated to general working capital and corporate purposes.CLSA, Huatai Financial, BOCOM International, BOCI Asia, CMB International, S","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0348783233.USD","LU1794554557.SGD","IE00B5MMRT66.SGD","LU2488822045.USD","02617","LU0348784397.USD","BK1161","LU1720050803.USD","09926","IE00BPRC5H50.USD","BK1574","LU0417516571.SGD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2541904690","title":"Akeso Inc. Receives NMPA Approval for Cadonilimab as First-Line Treatment for Cervical Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2541904690","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541904690?lang=en_us&edition=fundamental","pubTime":"2025-06-05 08:19","pubTimestamp":1749082781,"startTime":"0","endTime":"0","summary":"Akeso Inc. has announced a significant regulatory milestone, as the National Medical Products Administration  of China has approved the supplemental New Drug Application  for cadonilimab . This approval allows the use of cadonilimab in combination with platinum-based chemotherapy, with or without bevacizumab, as a first-line treatment for persistent, recurrent, or metastatic cervical cancer. This marks the third approved indication for cadonilimab and addresses the critical unmet needs for immune-based therapies for cervical cancer patients in China. The approval is based on the successful results of the COMPASSION-16/AK104-303 study, which demonstrated significant improvements in progression-free survival and overall survival.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL3qpqQ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","LU0417516571.SGD","LU2488822045.USD","LU0348783233.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU0348784397.USD","09926","IE00BPRC5H50.USD","LU1720050803.USD","LU1794554557.SGD","BK1161"],"gpt_icon":1},{"id":"2540478427","title":"Akeso Hits Snag with Less Favorable Clinical Trial Data for Lung Cancer Treatment; Shares Rise 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2540478427","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540478427?lang=en_us&edition=fundamental","pubTime":"2025-06-03 14:41","pubTimestamp":1748932906,"startTime":"0","endTime":"0","summary":"Akeso  and Summit Therapeutics suffered a setback after less favorable clinical data for its ivonescimab lung cancer drug diminished hopes for approval, the South China Morning Post reported Monday.The US Food and Drug Administration indicated a \"statistically significant\" overall survival benefit, from start of treatment to death, not just delayed tumor progression, is needed for US approval, the report said, citing Summit.The drug showed progression-free survival but had not yet shown a good enough survival benefit for patients in its study for US approval, the report said.Shares in Akeso jumped 7% during afternoon trading on Tuesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1720050803.USD","LU0348783233.USD","LU0417516571.SGD","IE00B543WZ88.USD","BK1574","IE00B5MMRT66.SGD","LU0348784397.USD","LU2488822045.USD","LU1794554557.SGD","BK1161","09926","IE00BPRC5H50.USD"],"gpt_icon":1},{"id":"2538120705","title":"Akeso Grants Share Options, Restricted Share Units","url":"https://stock-news.laohu8.com/highlight/detail?id=2538120705","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538120705?lang=en_us&edition=fundamental","pubTime":"2025-05-26 15:46","pubTimestamp":1748245608,"startTime":"0","endTime":"0","summary":"Akeso  granted 7,115,000 share options to 114 grantees under its share option scheme at an exercise price of HK$84.60 apiece, according to a Monday filing with the Hong Kong bourse.Chairperson Xia Yu is entitled to 3 million share options, the filing said.The biopharmaceutical company will also offer 3,420,000 restricted share units to 107 grantees, including Xia, who will be entitled to 2 million RSUs, and six other directors.The closing price of the shares is HK$83.15 per share, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","LU1720050803.USD","LU2488822045.USD","LU1794554557.SGD","BK1574","LU0348783233.USD","IE00B5MMRT66.SGD","LU0348784397.USD","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU0417516571.SGD","09926"],"gpt_icon":0},{"id":"2538491911","title":"Akeso Inc. Announces New Grant of Share Options and Restricted Share Units for Directors and Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2538491911","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538491911?lang=en_us&edition=fundamental","pubTime":"2025-05-26 07:41","pubTimestamp":1748216464,"startTime":"0","endTime":"0","summary":"Akeso Inc., a biopharmaceutical company incorporated in the Cayman Islands, announced on May 24, 2025, the grant of Share Options and Restricted Share Units  to recognize the contributions of its directors and existing employees. The announcement, made in compliance with the Listing Rules of the Stock Exchange of Hong Kong, disclosed the allocation of 4,080,000 Share Options to its board members, with Dr. XIA Yu, the chairwoman and executive director, receiving the largest portion of 3,000,000 options. Additionally, 3,035,000 Share Options were distributed among other company employees. The vesting of RSUs will be contingent upon individual performance targets, specifically tailored to the functions of each grantee, such as research and development, sales, and financial performance. This strategic move aims to align the interests of the company's leadership and staff with its operational and growth objectives.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250525:nNDL4BqbR0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1794554557.SGD","LU0417516571.SGD","LU2488822045.USD","09926","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","BK1574","LU1720050803.USD","LU0348783233.USD","BK1161","LU0348784397.USD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2536646754","title":"Pfizer Is Jumping Into a Hot Cancer-Drug Race. It May Have Overpaid. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2536646754","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536646754?lang=en_us&edition=fundamental","pubTime":"2025-05-20 22:46","pubTimestamp":1747752360,"startTime":"0","endTime":"0","summary":"Pfizer has thrown itself into the fiercest horse race in biopharma, saying late Monday it had bought the rights to an experimental cancer drug in a competitive and promising category. Analysts say it may have overpaid.The big move in biotech for the past few years has been for global players in the industry to make deals with Chinese biopharma companies to license PD-1/VEGF bispecific antibodies, a new type of tumor-killing treatment. The race heated up last June, when the U.S.-based biotech Summit Therapeutics said that its PD-1/VEGF bispecific antibody, licensed from a Chinese company called Akeso, beat Merck's Keytruda in lung-cancer patients.Now, everyone seems to be piling into the race. Merck announced a deal to license a Chinese PD-1/VEGF in November. BioNTech has one, too.Pfizer does have a partnership with Summit, announced in February, where the companies are testing Summit's PD-1/VEGF in combination with some Pfizer cancer drugs. But that deal wouldn't gi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","SG9999014575.USD","BK4568","SG9999003800.SGD","LU1116320901.HKD","BK4007","LU1069347547.HKD","LU1430594728.SGD","BK4588","LU0211331839.USD","IE00B5MMRT66.SGD","SG9999013999.USD","SG9999002224.SGD","09926","LU0234572021.USD","LU0208291251.USD","IE00BPRC5H50.USD","LU0225284248.USD","LU1941712348.USD","LU0965508806.USD","LU1066051811.HKD","PFE","LU1894683264.USD","BNTX","LU0306806265.USD","LU1989772840.SGD","IE00BFTCPJ56.SGD","LU0170899867.USD","LU0203345920.USD","LU1066053197.SGD","LU1035773651.USD","IE00B1BXHZ80.USD","LU1989772923.USD","LU0265550946.USD","LU1974910355.USD","LU0321505439.SGD","LU2361045086.USD","SMMT","IE0009355771.USD","LU1929549753.HKD","IE00BBT3K403.USD","BK4559","BK4535","IE0002141913.USD","IE000M9KFDE8.USD","LU0203347892.USD","BK4551","LU0106261372.USD","LU0965509010.AUD"],"gpt_icon":1},{"id":"2530647914","title":"Nomura Downgrades Akeso to Neutral From Buy, Adjusts Price Target to HK$99.66 From HK$75.14","url":"https://stock-news.laohu8.com/highlight/detail?id=2530647914","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530647914?lang=en_us&edition=fundamental","pubTime":"2025-04-28 18:55","pubTimestamp":1745837736,"startTime":"0","endTime":"0","summary":"Akeso (HKG:9926) has an average rating of buy and mean price target of HK$103.34, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09926"],"gpt_icon":0},{"id":"2530842448","title":"Akeso Gets China Nod for Lung Cancer Drug Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2530842448","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530842448?lang=en_us&edition=fundamental","pubTime":"2025-04-28 14:13","pubTimestamp":1745820829,"startTime":"0","endTime":"0","summary":"Akeso  obtained approval for a supplementary new drug application for ivonescimab to treat non-small cell lung cancer from China's National Medical Products Administration, an April 25 Hong Kong bourse filing said.The approval is for the indication of use of the drug as a monotherapy for the first-line treatment of PD-L1-positive  non-small cell lung cancer patients.This indication marks the second major approval for ivonescimab, according to the drug company.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0417516571.SGD","BK1161","LU1720050803.USD","BK1574","09926","LU0348783233.USD","LU0348784397.USD","IE00B543WZ88.USD","LU2488822045.USD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","LU1794554557.SGD"],"gpt_icon":1},{"id":"2530288139","title":"US FDA Approves Nasopharyngeal Carcinoma Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2530288139","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530288139?lang=en_us&edition=fundamental","pubTime":"2025-04-25 12:41","pubTimestamp":1745556098,"startTime":"0","endTime":"0","summary":"The US Food and Drug Administration  approved Akeso's penpulimab-kcqx combination with cisplatin or carboplatin and gemcitabine for the treatment of nasopharyngeal carcinoma.The drug, a differentiated PD-1 monoclonal antibody, is indicated for the treatment of recurrent or metastatic non-keratinizing nasopharyngeal carcinoma in adults, according to a Friday filing with the Hong Kong bourse.Chinese authorities have already approved the drug for first-line treatment of advanced nasopharyngeal carcinoma and second or later-line treatment of advanced nasopharyngeal carcinoma, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09926","BK1161","LU0417516571.SGD","BK1574","LU2488822045.USD","IE00B5MMRT66.SGD","LU1794554557.SGD","LU0348783233.USD","LU1720050803.USD","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU0348784397.USD"],"gpt_icon":0},{"id":"2530911847","title":"BRIEF-Akeso Says FDA Approved Anniko (Penpulimab-Kcqx, Pd-1) In Two Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2530911847","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530911847?lang=en_us&edition=fundamental","pubTime":"2025-04-25 08:56","pubTimestamp":1745542619,"startTime":"0","endTime":"0","summary":"BRIEF-Akeso Says FDA Approved Anniko  In Two Indications April 25  - Akeso 9926.HK:FDA APPROVED ANNIKO  IN TWO INDICATIONS FOR COMPREHENSIVE TREATMENT OF ADVANCED NASOPHARYNGEAL CARCINOMAFurther company coverage: 9926.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R23JY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1794554557.SGD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","BK1574","LU1720050803.USD","LU0348784397.USD","LU0348783233.USD","BK1161","LU2488822045.USD","IE00B543WZ88.USD","LU0417516571.SGD","09926"],"gpt_icon":0},{"id":"1104696869","title":"HK Movers | Biotech Stocks Jump With ImmuneOnco up 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104696869","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104696869?lang=en_us&edition=fundamental","pubTime":"2025-04-24 09:49","pubTimestamp":1745459345,"startTime":"0","endTime":"0","summary":"Biotech stocks surged in Hong Kong, with ImmuneOnco up 10%, RemeGen up 9%, Akeso and QYUNS up 6%, Lepu Biopharma up 5%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","02157","01541","09995","09926"],"gpt_icon":0},{"id":"2529448915","title":"Akeso's Lung Cancer Drug Meets Primary Endpoints in China Phase 3 Trial; Shares Rise 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529448915","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529448915?lang=en_us&edition=fundamental","pubTime":"2025-04-23 14:44","pubTimestamp":1745390664,"startTime":"0","endTime":"0","summary":"Akeso's  ivonescimab drug showed strong positive results in a phase 3 trial in China for advanced squamous non-small cell lung cancer, according to a Wednesday filing with the Hong Kong bourse.The drug also met the primary endpoint of progression-free survival and a favorable safety profile in a trial with 532 enrollees, the filing said.The trial assessed the capabilities of ivonescimab plus chemotherapy against  tislelizumab plus chemotherapy for the treatment of locally advanced or metastatic squamous non-small cell lung cancer, the filing said.Shares in the drug company nearly 5% during afternoon trading on Wednesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0348783233.USD","LU2488822045.USD","IE00B543WZ88.USD","BK1161","IE00B5MMRT66.SGD","LU0417516571.SGD","IE00BPRC5H50.USD","LU1720050803.USD","09926","BK1574","LU0348784397.USD","LU1794554557.SGD"],"gpt_icon":0},{"id":"1121380078","title":"HK Movers | Biotech Stocks Rally With Zai Lab up 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1121380078","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121380078?lang=en_us&edition=fundamental","pubTime":"2025-04-23 10:19","pubTimestamp":1745374765,"startTime":"0","endTime":"0","summary":"Biotech stocks rallied again in Hong Kong, with Zai Lab up 8%, Ascletis Pharma and Akeso up 6%, WuXi AppTec and WuXi Biologics up 3%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","02269","09926","02359","09688"],"gpt_icon":0},{"id":"2529310295","title":"Akeso's NDA for Plaque Psoriasis Drug Gets China Nod","url":"https://stock-news.laohu8.com/highlight/detail?id=2529310295","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529310295?lang=en_us&edition=fundamental","pubTime":"2025-04-22 15:05","pubTimestamp":1745305507,"startTime":"0","endTime":"0","summary":"Akeso's  new drug application  for the ebdarokimab injection recently obtained approval from China's National Medical Products Administration, a Monday Hong Kong bourse filing said.The approval was obtained for the treatment of moderate to severe plaque psoriasis in adult patients, according to the biopharmaceutical company.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BPRC5H50.USD","LU1720050803.USD","09926","IE00B5MMRT66.SGD","BK1574","LU0348784397.USD","LU0417516571.SGD","LU1794554557.SGD","BK1161","LU2488822045.USD","IE00B543WZ88.USD","LU0348783233.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":48,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09926\",params:#limit:5,,,undefined,":[{"date":"2025-03-30","symbol":"09926","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743298200000,"name":null,"time":"Post Market","dateTimestamp":1743264000000,"actualEps":null},{"date":"2024-08-28","symbol":"09926","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724808600000,"name":null,"time":"","dateTimestamp":1724774400000,"actualEps":null},{"date":"2024-03-18","symbol":"09926","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1710725400000,"name":null,"time":"","dateTimestamp":1710691200000,"actualEps":null},{"date":"2023-08-29","symbol":"09926","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693272600000,"name":null,"time":"","dateTimestamp":1693238400000,"actualEps":null},{"market":"HK","date":"2023-04-27","symbol":"09926","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1682524800000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09926\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09926\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.5238,"hold":0.0476,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5238,"analysts":21,"updateTime":1752854400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09926\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09926","date":"2025-08-05","current":-260.24436,"percent":0,"low":-260.24436,"twenty":-59.773257,"median":-23.989446,"eighty":13.587555,"high":20.221708,"avg":-31.837765,"sd":45.527867,"marketCap":146304753688},"quantilePoints":[{"date":"2020-08-07","current":-61.60528,"twenty":-71.199223,"median":-62.665648,"eighty":-55.108469,"marketCap":22982069539},{"date":"2020-08-14","current":-60.398898,"twenty":-70.692859,"median":-61.425183,"eighty":-55.354665,"marketCap":22588540951},{"date":"2020-08-21","current":-65.573062,"twenty":-70.162934,"median":-62.07047,"eighty":-55.490937,"marketCap":24634889608},{"date":"2020-08-28","current":-62.258841,"twenty":-69.624858,"median":-61.507641,"eighty":-55.875802,"marketCap":23572362421},{"date":"2020-09-04","current":-56.454938,"twenty":-69.299363,"median":-61.279481,"eighty":-56.312276,"marketCap":21447308046},{"date":"2020-09-11","current":-59.39532,"twenty":-69.034548,"median":-61.149297,"eighty":-56.381895,"marketCap":22588540951},{"date":"2020-09-18","current":-23.213534,"twenty":-68.783672,"median":-61.157004,"eighty":-56.381895,"marketCap":23847832432},{"date":"2020-09-25","current":-20.580693,"twenty":-68.608413,"median":-60.769842,"eighty":-55.354665,"marketCap":20975073740},{"date":"2020-09-30","current":-21.520592,"twenty":-68.49576,"median":-60.537717,"eighty":-54.51941,"marketCap":22037600928},{"date":"2020-10-09","current":-20.533232,"twenty":-68.261016,"median":-60.351714,"eighty":-53.10451,"marketCap":21329249469},{"date":"2020-10-16","current":-20.579561,"twenty":-67.599319,"median":-60.014098,"eighty":-50.561624,"marketCap":21368602328},{"date":"2020-10-23","current":-18.390768,"twenty":-65.566444,"median":-59.898011,"eighty":-36.752532,"marketCap":19125489376},{"date":"2020-10-30","current":-18.387929,"twenty":-65.53997,"median":-59.39532,"eighty":-22.333682,"marketCap":19125489376},{"date":"2020-11-06","current":-18.960772,"twenty":-65.539086,"median":-59.096072,"eighty":-21.714319,"marketCap":19951899411},{"date":"2020-11-13","current":-17.861227,"twenty":-65.495719,"median":-58.967855,"eighty":-21.20377,"marketCap":18810666506},{"date":"2020-11-20","current":-18.195519,"twenty":-65.439452,"median":-58.396831,"eighty":-20.827083,"marketCap":19282900812},{"date":"2020-11-27","current":-18.163703,"twenty":-65.051015,"median":-57.55027,"eighty":-20.533232,"marketCap":19204195094},{"date":"2020-12-04","current":-19.807773,"twenty":-64.515903,"median":-57.279422,"eighty":-20.022532,"marketCap":21093132316},{"date":"2020-12-11","current":-21.33702,"twenty":-64.452305,"median":-56.818854,"eighty":-20.137955,"marketCap":22667246668},{"date":"2020-12-18","current":-24.630996,"twenty":-64.186949,"median":-56.363634,"eighty":-20.421683,"marketCap":26209003960},{"date":"2020-12-24","current":-26.970119,"twenty":-63.818518,"median":-55.820181,"eighty":-20.432553,"marketCap":28727586924},{"date":"2020-12-31","current":-28.06698,"twenty":-63.629518,"median":-55.339775,"eighty":-20.494047,"marketCap":29908172688},{"date":"2021-01-08","current":-32.570823,"twenty":-63.597221,"median":-55.265323,"eighty":-20.51364,"marketCap":34984691473},{"date":"2021-01-15","current":-37.631162,"twenty":-63.40952,"median":-54.292281,"eighty":-20.570295,"marketCap":40403477353},{"date":"2021-01-22","current":-41.643907,"twenty":-63.295257,"median":-53.301351,"eighty":-20.580467,"marketCap":44693027527},{"date":"2021-01-29","current":-40.849406,"twenty":-63.217929,"median":-51.221035,"eighty":-20.705895,"marketCap":44202793221},{"date":"2021-02-05","current":-42.462881,"twenty":-63.20331,"median":-50.765107,"eighty":-20.737196,"marketCap":45673496138},{"date":"2021-02-11","current":-44.298428,"twenty":-63.199738,"median":-50.518886,"eighty":-20.809106,"marketCap":47716139078},{"date":"2021-02-19","current":-44.620302,"twenty":-63.148699,"median":-50.046102,"eighty":-20.827888,"marketCap":48083814807},{"date":"2021-02-26","current":-38.677591,"twenty":-62.923489,"median":-46.003712,"eighty":-21.003278,"marketCap":41588210258},{"date":"2021-03-05","current":-36.070462,"twenty":-62.63965,"median":-44.620302,"eighty":-21.129156,"marketCap":38687657283},{"date":"2021-03-12","current":-33.577269,"twenty":-62.438134,"median":-44.247826,"eighty":-21.158012,"marketCap":35950515744},{"date":"2021-03-19","current":-35.993074,"twenty":-62.327407,"median":-43.908841,"eighty":-21.185375,"marketCap":38524245848},{"date":"2021-03-26","current":-37.072786,"twenty":-62.202297,"median":-42.138278,"eighty":-21.221991,"marketCap":39504714459},{"date":"2021-04-01","current":-41.283195,"twenty":-62.015041,"median":-41.751169,"eighty":-21.266862,"marketCap":43875970351},{"date":"2021-04-09","current":-31.196593,"twenty":-61.70772,"median":-41.695813,"eighty":-21.319481,"marketCap":43590000339},{"date":"2021-04-16","current":-30.642009,"twenty":-61.527169,"median":-40.849406,"eighty":-21.393706,"marketCap":42977207457},{"date":"2021-04-23","current":-31.96013,"twenty":-61.441675,"median":-40.344151,"eighty":-21.433299,"marketCap":44938144680},{"date":"2021-04-30","current":-30.816187,"twenty":-61.312504,"median":-39.558199,"eighty":-21.441654,"marketCap":43508294622},{"date":"2021-05-07","current":-28.864106,"twenty":-61.27851,"median":-38.69692,"eighty":-21.489217,"marketCap":41016270235},{"date":"2021-05-14","current":-29.343194,"twenty":-61.208677,"median":-38.024901,"eighty":-21.636828,"marketCap":41669915976},{"date":"2021-05-21","current":-32.815059,"twenty":-61.158545,"median":-37.656345,"eighty":-21.839766,"marketCap":46613111890},{"date":"2021-05-28","current":-34.118192,"twenty":-61.102433,"median":-37.609185,"eighty":-22.049324,"marketCap":48941724842},{"date":"2021-06-04","current":-35.625611,"twenty":-60.979677,"median":-37.553441,"eighty":-22.116923,"marketCap":50861809206},{"date":"2021-06-10","current":-37.08623,"twenty":-60.769842,"median":-37.072786,"eighty":-22.258985,"marketCap":52986157863},{"date":"2021-06-18","current":-35.659842,"twenty":-60.584234,"median":-36.485136,"eighty":-22.270088,"marketCap":50494133476},{"date":"2021-06-25","current":-36.773665,"twenty":-60.537647,"median":-36.47778,"eighty":-22.279086,"marketCap":51923983534},{"date":"2021-06-30","current":-36.160141,"twenty":-60.48212,"median":-36.485136,"eighty":-22.301737,"marketCap":51188632076},{"date":"2021-07-09","current":-33.001535,"twenty":-60.380024,"median":-36.358401,"eighty":-22.333501,"marketCap":46572259032},{"date":"2021-07-16","current":-33.61015,"twenty":-60.247205,"median":-36.160141,"eighty":-22.684742,"marketCap":47430169066},{"date":"2021-07-23","current":-30.660269,"twenty":-60.081955,"median":-36.081197,"eighty":-23.212212,"marketCap":43263177469},{"date":"2021-07-30","current":-29.749657,"twenty":-60.025123,"median":-35.993074,"eighty":-23.780519,"marketCap":42119297422},{"date":"2021-08-06","current":-26.92917,"twenty":-59.948494,"median":-35.665203,"eighty":-24.743522,"marketCap":38034011542},{"date":"2021-08-13","current":-25.592675,"twenty":-59.918873,"median":-35.597545,"eighty":-24.965673,"marketCap":36195632896},{"date":"2021-08-20","current":-20.885732,"twenty":-59.826938,"median":-35.459665,"eighty":-24.434422,"marketCap":29454911194},{"date":"2021-08-27","current":-21.082492,"twenty":-59.613719,"median":-35.394103,"eighty":-23.176546,"marketCap":29863439782},{"date":"2021-09-03","current":-31.115126,"twenty":-59.45425,"median":-35.211108,"eighty":-23.023412,"marketCap":34806635697},{"date":"2021-09-10","current":-32.055246,"twenty":-59.359698,"median":-34.971061,"eighty":-23.122707,"marketCap":35950515744},{"date":"2021-09-17","current":-31.163903,"twenty":-59.210176,"median":-34.572405,"eighty":-23.198629,"marketCap":34847488556},{"date":"2021-09-24","current":-31.295563,"twenty":-59.102123,"median":-34.437371,"eighty":-23.212212,"marketCap":35010899991},{"date":"2021-09-30","current":-31.154784,"twenty":-59.047908,"median":-34.407249,"eighty":-23.447883,"marketCap":34970047132},{"date":"2021-10-08","current":-29.845898,"twenty":-58.976264,"median":-34.085183,"eighty":-24.385279,"marketCap":33499344216},{"date":"2021-10-15","current":-32.807984,"twenty":-58.969537,"median":-33.89682,"eighty":-24.581853,"marketCap":36849278637},{"date":"2021-10-22","current":-33.585285,"twenty":-58.897857,"median":-33.786096,"eighty":-24.856047,"marketCap":37993158684},{"date":"2021-10-29","current":-31.568779,"twenty":-58.531823,"median":-33.627637,"eighty":-25.019036,"marketCap":35623692873},{"date":"2021-11-05","current":-28.336247,"twenty":-58.387259,"median":-33.581277,"eighty":-25.13981,"marketCap":32028641299},{"date":"2021-11-12","current":-31.135474,"twenty":-58.165915,"median":-33.566565,"eighty":-25.305935,"marketCap":35337722862},{"date":"2021-11-19","current":-36.658551,"twenty":-57.747713,"median":-33.576384,"eighty":-25.505551,"marketCap":41547357399},{"date":"2021-11-26","current":-34.737009,"twenty":-57.465203,"median":-33.61015,"eighty":-25.671516,"marketCap":39382155883},{"date":"2021-12-03","current":-31.939354,"twenty":-57.376977,"median":-33.627637,"eighty":-26.141756,"marketCap":36277338614},{"date":"2021-12-10","current":-30.771813,"twenty":-57.264113,"median":-33.577269,"eighty":-26.43668,"marketCap":35010899991},{"date":"2021-12-17","current":-26.05017,"twenty":-56.996271,"median":-33.456271,"eighty":-26.43668,"marketCap":29618322630},{"date":"2021-12-24","current":-24.338156,"twenty":-56.834726,"median":-33.106388,"eighty":-25.505551,"marketCap":27698238266},{"date":"2021-12-31","current":-24.356969,"twenty":-56.799582,"median":-33.044261,"eighty":-25.17902,"marketCap":27779943984},{"date":"2022-01-07","current":-20.242995,"twenty":-23.086945,"median":-21.779811,"eighty":-19.899701,"marketCap":23000159504},{"date":"2022-01-14","current":-20.701287,"twenty":-22.600464,"median":-21.033383,"eighty":-20.391327,"marketCap":23572099527},{"date":"2022-01-21","current":-18.577865,"twenty":-21.986595,"median":-20.680988,"eighty":-19.350843,"marketCap":21202633717},{"date":"2022-01-28","current":-14.534275,"twenty":-21.562934,"median":-20.260299,"eighty":-18.52558,"marketCap":16545407814},{"date":"2022-02-04","current":-14.146452,"twenty":-21.41835,"median":-20.123216,"eighty":-17.613539,"marketCap":16096026367},{"date":"2022-02-11","current":-13.816944,"twenty":-21.209422,"median":-19.299968,"eighty":-14.985471,"marketCap":15752862353},{"date":"2022-02-18","current":-13.849256,"twenty":-20.857344,"median":-18.911796,"eighty":-14.543623,"marketCap":15867250357},{"date":"2022-02-25","current":-14.199347,"twenty":-20.701287,"median":-17.613539,"eighty":-14.146452,"marketCap":16308461232},{"date":"2022-03-04","current":-14.080132,"twenty":-20.680988,"median":-15.318994,"eighty":-14.146452,"marketCap":16177732084},{"date":"2022-03-11","current":-11.936356,"twenty":-20.490215,"median":-14.985471,"eighty":-13.996814,"marketCap":13693878269},{"date":"2022-03-18","current":-11.726724,"twenty":-20.277602,"median":-14.700549,"eighty":-13.379502,"marketCap":13399737686},{"date":"2022-03-25","current":-12.670051,"twenty":-20.242995,"median":-14.554967,"eighty":-13.072377,"marketCap":14478253158},{"date":"2022-04-01","current":-9.59311,"twenty":-20.003436,"median":-14.538949,"eighty":-12.331764,"marketCap":12697068515},{"date":"2022-04-08","current":-10.156641,"twenty":-19.508494,"median":-14.196743,"eighty":-11.833638,"marketCap":13448761116},{"date":"2022-04-14","current":-9.530673,"twenty":-19.333884,"median":-14.131899,"eighty":-11.51878,"marketCap":12599021653},{"date":"2022-04-22","current":-8.780037,"twenty":-19.299831,"median":-14.060726,"eighty":-10.573986,"marketCap":11389777033},{"date":"2022-04-29","current":-9.576611,"twenty":-19.278065,"median":-13.849256,"eighty":-10.115287,"marketCap":12223175352},{"date":"2022-05-06","current":-7.86231,"twenty":-19.112154,"median":-13.498553,"eighty":-9.579911,"marketCap":9951756403},{"date":"2022-05-13","current":-8.110711,"twenty":-18.577865,"median":-13.379502,"eighty":-9.437455,"marketCap":10082485551},{"date":"2022-05-20","current":-9.061494,"twenty":-18.447152,"median":-13.096379,"eighty":-8.947629,"marketCap":11422459320},{"date":"2022-05-27","current":-8.809867,"twenty":-17.613539,"median":-12.670051,"eighty":-8.780037,"marketCap":11095636450},{"date":"2022-06-02","current":-11.227787,"twenty":-16.802517,"median":-12.331764,"eighty":-8.803901,"marketCap":14216794862},{"date":"2022-06-10","current":-12.109337,"twenty":-15.675042,"median":-12.221978,"eighty":-8.825148,"marketCap":15229945760},{"date":"2022-06-17","current":-11.667379,"twenty":-15.244074,"median":-11.936356,"eighty":-8.923897,"marketCap":14658005737},{"date":"2022-06-24","current":-16.485913,"twenty":-15.494316,"median":-12.221978,"eighty":-9.038721,"marketCap":20794105129},{"date":"2022-06-30","current":-14.957001,"twenty":-15.895364,"median":-12.380422,"eighty":-9.079607,"marketCap":18833167906},{"date":"2022-07-08","current":-15.913959,"twenty":-16.531452,"median":-12.638751,"eighty":-9.104893,"marketCap":20058753670},{"date":"2022-07-15","current":-15.322331,"twenty":-16.45611,"median":-12.887919,"eighty":-9.149933,"marketCap":19134050754},{"date":"2022-07-22","current":-14.807486,"twenty":-16.221667,"median":-13.200862,"eighty":-9.216155,"marketCap":18503257872},{"date":"2022-07-29","current":-14.117198,"twenty":-15.979822,"median":-13.449665,"eighty":-9.360153,"marketCap":17662200696},{"date":"2022-08-05","current":-15.298986,"twenty":-15.838747,"median":-13.498553,"eighty":-9.442,"marketCap":19091997895},{"date":"2022-08-12","current":-15.143556,"twenty":-15.77936,"median":-13.923035,"eighty":-9.496416,"marketCap":18923786460},{"date":"2022-08-19","current":-14.616817,"twenty":-15.77936,"median":-14.080132,"eighty":-9.558236,"marketCap":18082729284},{"date":"2022-08-26","current":-14.756101,"twenty":-15.738632,"median":-14.060726,"eighty":-9.58651,"marketCap":21573116564},{"date":"2022-09-02","current":-14.751536,"twenty":-15.714766,"median":-14.080132,"eighty":-9.724865,"marketCap":21489010846},{"date":"2022-09-09","current":-14.98178,"twenty":-15.703366,"median":-14.105484,"eighty":-9.977712,"marketCap":21741327999},{"date":"2022-09-16","current":-13.542084,"twenty":-15.658514,"median":-14.086951,"eighty":-10.115287,"marketCap":19470473624},{"date":"2022-09-23","current":-12.107338,"twenty":-15.550768,"median":-14.041319,"eighty":-10.199224,"marketCap":17073460672},{"date":"2022-09-30","current":-12.91765,"twenty":-15.461818,"median":-13.978573,"eighty":-10.287783,"marketCap":18250940719},{"date":"2022-10-07","current":-16.281937,"twenty":-15.588998,"median":-14.018764,"eighty":-10.343921,"marketCap":23002913763},{"date":"2022-10-14","current":-15.674276,"twenty":-15.588998,"median":-14.040715,"eighty":-10.440625,"marketCap":21909539434},{"date":"2022-10-21","current":-18.781307,"twenty":-15.710601,"median":-14.070137,"eighty":-10.570074,"marketCap":26072772456},{"date":"2022-10-28","current":-18.085263,"twenty":-15.888888,"median":-14.117198,"eighty":-10.76408,"marketCap":25063503844},{"date":"2022-11-04","current":-18.001131,"twenty":-16.380537,"median":-14.170295,"eighty":-10.773453,"marketCap":25189662421},{"date":"2022-11-11","current":-17.246398,"twenty":-16.644748,"median":-14.199347,"eighty":-10.843556,"marketCap":24348605245},{"date":"2022-11-18","current":-21.310798,"twenty":-17.050284,"median":-14.308051,"eighty":-11.043704,"marketCap":29983688324},{"date":"2022-11-25","current":-18.980602,"twenty":-17.498612,"median":-14.382807,"eighty":-11.22006,"marketCap":26493301044},{"date":"2022-12-02","current":-19.013979,"twenty":-17.995008,"median":-14.534799,"eighty":-11.242055,"marketCap":26997935349},{"date":"2022-12-09","current":-24.062263,"twenty":-18.437795,"median":-14.543856,"eighty":-11.359054,"marketCap":34483344216},{"date":"2022-12-16","current":-24.530301,"twenty":-18.889555,"median":-14.574904,"eighty":-11.602588,"marketCap":35072084239},{"date":"2022-12-23","current":-25.228352,"twenty":-19.041941,"median":-14.612379,"eighty":-11.627361,"marketCap":36081352850},{"date":"2022-12-30","current":-24.983629,"twenty":-19.09779,"median":-14.616563,"eighty":-11.655751,"marketCap":36165458568},{"date":"2023-01-06","current":-26.109825,"twenty":-19.246994,"median":-14.727609,"eighty":-11.666513,"marketCap":38183995790},{"date":"2023-01-13","current":-27.482086,"twenty":-19.35432,"median":-14.788719,"eighty":-11.675194,"marketCap":40959484471},{"date":"2023-01-20","current":-27.207673,"twenty":-19.72973,"median":-14.927803,"eighty":-11.681264,"marketCap":40202533012},{"date":"2023-01-27","current":-29.02317,"twenty":-19.973183,"median":-14.953302,"eighty":-11.681837,"marketCap":42893915976},{"date":"2023-02-03","current":-27.684735,"twenty":-20.135985,"median":-14.979187,"eighty":-11.694899,"marketCap":41127695906},{"date":"2023-02-10","current":-25.345976,"twenty":-20.490215,"median":-14.987339,"eighty":-11.726724,"marketCap":37427044332},{"date":"2023-02-17","current":-24.322978,"twenty":-20.857344,"median":-15.034554,"eighty":-11.784491,"marketCap":35576718544},{"date":"2023-02-24","current":-24.100109,"twenty":-21.41835,"median":-15.060613,"eighty":-11.860367,"marketCap":34819767086},{"date":"2023-03-03","current":-25.36278,"twenty":-22.807081,"median":-15.131721,"eighty":-11.936356,"marketCap":36880357167},{"date":"2023-03-10","current":-22.900092,"twenty":-23.768741,"median":-23.203261,"eighty":-23.03994,"marketCap":33053547016},{"date":"2023-03-17","current":-29.09369,"twenty":-36.802165,"median":-25.36278,"eighty":-15.020812,"marketCap":38688630096},{"date":"2023-03-24","current":-25.324343,"twenty":-36.777216,"median":-25.389232,"eighty":-15.036479,"marketCap":34062815628},{"date":"2023-03-31","current":-25.456261,"twenty":-36.704597,"median":-25.488573,"eighty":-15.049117,"marketCap":33978709910},{"date":"2023-04-06","current":-27.774061,"twenty":-36.623868,"median":-25.540624,"eighty":-15.058257,"marketCap":37048568602},{"date":"2023-04-14","current":-29.730818,"twenty":-36.485136,"median":-25.637411,"eighty":-15.064541,"marketCap":39697898707},{"date":"2023-04-21","current":-26.784111,"twenty":-36.470425,"median":-25.724076,"eighty":-15.129637,"marketCap":35744929980},{"date":"2023-04-28","current":-27.207269,"twenty":-36.436465,"median":-26.010547,"eighty":-15.131721,"marketCap":36039299991},{"date":"2023-05-05","current":-28.335447,"twenty":-36.311562,"median":-26.064869,"eighty":-15.141189,"marketCap":37595255767},{"date":"2023-05-12","current":-27.159579,"twenty":-36.18971,"median":-26.086367,"eighty":-15.143863,"marketCap":35786982838},{"date":"2023-05-19","current":-24.342298,"twenty":-36.161524,"median":-26.085247,"eighty":-15.156,"marketCap":31623749817},{"date":"2023-05-25","current":-24.063272,"twenty":-36.158475,"median":-26.064869,"eighty":-15.180082,"marketCap":31203221229},{"date":"2023-06-02","current":-23.645458,"twenty":-36.149195,"median":-25.984476,"eighty":-15.257042,"marketCap":30488322630},{"date":"2023-06-09","current":-23.222359,"twenty":-36.112659,"median":-25.723039,"eighty":-15.312993,"marketCap":29899582606},{"date":"2023-06-16","current":-24.58122,"twenty":-36.07905,"median":-25.633881,"eighty":-15.343575,"marketCap":31497591241},{"date":"2023-06-23","current":-21.944137,"twenty":-36.043198,"median":-25.488573,"eighty":-15.365065,"marketCap":27965151102},{"date":"2023-06-30","current":-23.543047,"twenty":-35.998611,"median":-25.389232,"eighty":-15.403178,"marketCap":29731371171},{"date":"2023-07-07","current":-23.989446,"twenty":-35.969849,"median":-25.36278,"eighty":-15.455833,"marketCap":30236005477},{"date":"2023-07-14","current":-24.41425,"twenty":-35.912278,"median":-25.312393,"eighty":-15.498928,"marketCap":31203221229},{"date":"2023-07-21","current":-24.59436,"twenty":-35.843663,"median":-25.202538,"eighty":-15.562817,"marketCap":31287326947},{"date":"2023-07-28","current":-28.426335,"twenty":-35.766034,"median":-25.264398,"eighty":-15.623426,"marketCap":36123405709},{"date":"2023-08-04","current":-24.11733,"twenty":-35.704573,"median":-25.300444,"eighty":-15.66297,"marketCap":30698586924},{"date":"2023-08-11","current":-22.294,"twenty":-35.666275,"median":-25.201022,"eighty":-15.683018,"marketCap":28217468254},{"date":"2023-08-18","current":-21.752014,"twenty":-35.64615,"median":-25.173816,"eighty":-15.703366,"marketCap":27334358220},{"date":"2023-08-25","current":-22.10921,"twenty":-35.616771,"median":-25.07893,"eighty":-15.714766,"marketCap":27796939666},{"date":"2023-09-01","current":13.494719,"twenty":-35.601124,"median":-25.008455,"eighty":-15.66297,"marketCap":28974419713},{"date":"2023-09-08","current":13.695117,"twenty":-35.550756,"median":-24.944029,"eighty":-15.455833,"marketCap":29058525430},{"date":"2023-09-15","current":14.848421,"twenty":-35.47221,"median":-24.903626,"eighty":-15.308324,"marketCap":31749908394},{"date":"2023-09-22","current":14.814862,"twenty":-35.438003,"median":-24.827647,"eighty":-15.14371,"marketCap":31539644100},{"date":"2023-09-29","current":14.197918,"twenty":-35.396385,"median":-24.772153,"eighty":-15.059828,"marketCap":30278058336},{"date":"2023-10-06","current":13.889059,"twenty":-35.370319,"median":-24.700469,"eighty":-15.007069,"marketCap":29605212595},{"date":"2023-10-13","current":15.431226,"twenty":-35.30592,"median":-24.632761,"eighty":-14.979706,"marketCap":32843282722},{"date":"2023-10-20","current":14.94053,"twenty":-35.232247,"median":-24.59436,"eighty":-14.914724,"marketCap":31749908394},{"date":"2023-10-27","current":16.35255,"twenty":-35.175876,"median":-24.58122,"eighty":-14.756101,"marketCap":34735661368},{"date":"2023-11-03","current":17.592659,"twenty":-35.129074,"median":-24.511377,"eighty":-14.616308,"marketCap":37469097190},{"date":"2023-11-10","current":18.939266,"twenty":-34.971061,"median":-24.417444,"eighty":-14.569406,"marketCap":40328691589},{"date":"2023-11-17","current":18.319814,"twenty":-34.968612,"median":-24.399566,"eighty":-14.535322,"marketCap":39361475836},{"date":"2023-11-24","current":18.189638,"twenty":-34.895357,"median":-24.342298,"eighty":-14.371526,"marketCap":39403528695},{"date":"2023-12-01","current":18.752497,"twenty":-34.737009,"median":-24.330293,"eighty":-14.199347,"marketCap":40791273036},{"date":"2023-12-08","current":16.771041,"twenty":-34.685609,"median":-24.255162,"eighty":-14.117346,"marketCap":36333670003},{"date":"2023-12-15","current":17.832719,"twenty":-34.615488,"median":-24.15298,"eighty":-14.060142,"marketCap":38856841531},{"date":"2023-12-22","current":16.203086,"twenty":-34.602221,"median":-24.100109,"eighty":-13.960331,"marketCap":35282348533},{"date":"2023-12-29","current":17.826838,"twenty":-34.566441,"median":-24.075355,"eighty":-13.84838,"marketCap":39025052966},{"date":"2024-01-05","current":16.831364,"twenty":-34.502078,"median":-24.025855,"eighty":-13.7643,"marketCap":36585987156},{"date":"2024-01-12","current":17.634525,"twenty":-34.43816,"median":-23.91516,"eighty":-13.515965,"marketCap":38352207225},{"date":"2024-01-19","current":16.051677,"twenty":-34.428025,"median":-23.817977,"eighty":-13.388012,"marketCap":34861819945},{"date":"2024-01-26","current":16.269899,"twenty":-34.417805,"median":-23.667454,"eighty":-13.261099,"marketCap":35198242815},{"date":"2024-02-02","current":15.531605,"twenty":-34.408725,"median":-23.587311,"eighty":-13.092715,"marketCap":33558181322},{"date":"2024-02-09","current":15.823479,"twenty":-34.287198,"median":-23.509747,"eighty":-12.88456,"marketCap":34357185639},{"date":"2024-02-16","current":17.001239,"twenty":-34.118192,"median":-23.29296,"eighty":-12.670051,"marketCap":36922410026},{"date":"2024-02-23","current":17.733723,"twenty":-34.052175,"median":-23.261464,"eighty":-12.429079,"marketCap":38310154366},{"date":"2024-03-01","current":18.170113,"twenty":-33.918444,"median":-23.222586,"eighty":-12.109337,"marketCap":39277370119},{"date":"2024-03-08","current":18.375936,"twenty":-33.875196,"median":-23.212231,"eighty":-11.784491,"marketCap":39739951566},{"date":"2024-03-15","current":20.221708,"twenty":-33.786096,"median":-23.186995,"eighty":-11.680404,"marketCap":43692920293},{"date":"2024-03-22","current":17.596046,"twenty":-33.777607,"median":-23.165857,"eighty":-11.598761,"marketCap":38772735813},{"date":"2024-03-28","current":17.863111,"twenty":-33.671621,"median":-23.133172,"eighty":-11.174522,"marketCap":39235317260},{"date":"2024-04-05","current":17.790526,"twenty":-33.631134,"median":-23.073507,"eighty":-10.781195,"marketCap":39050158637},{"date":"2024-04-12","current":19.515107,"twenty":-33.600204,"median":-23.002422,"eighty":-10.363031,"marketCap":42859930212},{"date":"2024-04-19","current":17.322126,"twenty":-33.582079,"median":-22.887987,"eighty":-9.922708,"marketCap":38011130026},{"date":"2024-04-26","current":19.239838,"twenty":-33.576561,"median":-22.815578,"eighty":-9.479287,"marketCap":42167244471},{"date":"2024-05-03","current":19.371749,"twenty":-33.573712,"median":-22.807081,"eighty":-9.18811,"marketCap":42427001624},{"date":"2024-05-10","current":19.700553,"twenty":-33.522448,"median":-22.755385,"eighty":-8.970402,"marketCap":43249565941},{"date":"2024-05-17","current":19.23578,"twenty":-33.345978,"median":-22.735553,"eighty":-8.780037,"marketCap":42167244471},{"date":"2024-05-24","current":14.667701,"twenty":-33.217784,"median":-22.607363,"eighty":-8.675073,"marketCap":32080008370},{"date":"2024-05-31","current":17.401421,"twenty":-33.106388,"median":-22.460124,"eighty":-8.554056,"marketCap":38097715744},{"date":"2024-06-07","current":16.096502,"twenty":-33.061925,"median":-22.417733,"eighty":-8.291628,"marketCap":35197094204},{"date":"2024-06-14","current":15.794192,"twenty":-33.047794,"median":-22.339227,"eighty":-8.117822,"marketCap":34504408463},{"date":"2024-06-21","current":14.159201,"twenty":-33.01008,"median":-22.315076,"eighty":-7.860137,"marketCap":30867808324},{"date":"2024-06-28","current":14.999486,"twenty":-32.90826,"median":-22.280642,"eighty":13.494356,"marketCap":32686108394},{"date":"2024-07-05","current":15.459781,"twenty":-32.881624,"median":-22.258985,"eighty":13.627238,"marketCap":33681844146},{"date":"2024-07-12","current":15.952998,"twenty":-32.86657,"median":-22.065202,"eighty":13.703744,"marketCap":34807458475},{"date":"2024-07-19","current":15.972541,"twenty":-32.832239,"median":-21.944137,"eighty":13.863497,"marketCap":34850751334},{"date":"2024-07-26","current":16.071567,"twenty":-32.814226,"median":-21.7966,"eighty":14.148348,"marketCap":35197094204},{"date":"2024-08-02","current":16.61499,"twenty":-32.811697,"median":-21.752014,"eighty":14.411832,"marketCap":36366001392},{"date":"2024-08-09","current":17.212345,"twenty":-32.808943,"median":-21.597174,"eighty":14.509977,"marketCap":37924544308},{"date":"2024-08-16","current":17.657405,"twenty":-32.804956,"median":-21.439655,"eighty":14.640353,"marketCap":38920280061},{"date":"2024-08-23","current":17.9547,"twenty":-32.79969,"median":-21.418042,"eighty":14.703604,"marketCap":39742844378},{"date":"2024-08-30","current":-52.624506,"twenty":-32.804956,"median":-21.417734,"eighty":14.818346,"marketCap":42513587341},{"date":"2024-09-06","current":-51.635037,"twenty":-32.832239,"median":-21.438942,"eighty":14.78042,"marketCap":41734315883},{"date":"2024-09-13","current":-66.216902,"twenty":-33.018625,"median":-21.520592,"eighty":14.703604,"marketCap":53380094900},{"date":"2024-09-20","current":-69.932725,"twenty":-33.173226,"median":-21.714319,"eighty":14.662246,"marketCap":56713645028},{"date":"2024-09-27","current":-71.531113,"twenty":-33.576561,"median":-21.771586,"eighty":14.652247,"marketCap":58358773662},{"date":"2024-10-04","current":-79.320454,"twenty":-33.638129,"median":-21.813706,"eighty":14.649255,"marketCap":64419773894},{"date":"2024-10-10","current":-69.213885,"twenty":-33.875196,"median":-21.986037,"eighty":14.648182,"marketCap":55847787852},{"date":"2024-10-18","current":-74.646599,"twenty":-34.399868,"median":-22.081407,"eighty":14.635134,"marketCap":59917316579},{"date":"2024-10-25","current":-77.719883,"twenty":-34.441314,"median":-22.265924,"eighty":14.560741,"marketCap":62380223732},{"date":"2024-11-01","current":-76.214752,"twenty":-34.685609,"median":-22.294,"eighty":14.556702,"marketCap":61213399403},{"date":"2024-11-08","current":-76.2814,"twenty":-34.971061,"median":-22.333531,"eighty":14.515997,"marketCap":60989010109},{"date":"2024-11-15","current":-78.00551,"twenty":-35.320815,"median":-22.40582,"eighty":14.505964,"marketCap":61707055850},{"date":"2024-11-22","current":-81.958791,"twenty":-35.480573,"median":-22.437728,"eighty":14.479729,"marketCap":64803628107},{"date":"2024-11-29","current":-83.036127,"twenty":-35.659842,"median":-22.470599,"eighty":14.463817,"marketCap":65611429565},{"date":"2024-12-06","current":-74.237179,"twenty":-35.878177,"median":-22.720101,"eighty":14.435399,"marketCap":58520727875},{"date":"2024-12-13","current":-72.615659,"twenty":-36.070462,"median":-22.745547,"eighty":14.396121,"marketCap":57129514252},{"date":"2024-12-20","current":-69.730236,"twenty":-36.160141,"median":-22.79318,"eighty":14.28027,"marketCap":54616354159},{"date":"2024-12-27","current":-68.121477,"twenty":-36.342788,"median":-22.81524,"eighty":14.230859,"marketCap":53314896254},{"date":"2025-01-03","current":-66.794572,"twenty":-36.589185,"median":-22.863096,"eighty":14.182431,"marketCap":52327583360},{"date":"2025-01-10","current":-64.575988,"twenty":-36.921451,"median":-22.916115,"eighty":14.151966,"marketCap":50397835432},{"date":"2025-01-17","current":-67.97132,"twenty":-37.388459,"median":-23.037405,"eighty":14.124517,"marketCap":53090506960},{"date":"2025-01-24","current":-71.487894,"twenty":-37.630978,"median":-23.112092,"eighty":14.06824,"marketCap":56187079217},{"date":"2025-01-28","current":-69.159217,"twenty":-37.749998,"median":-23.133265,"eighty":14.036856,"marketCap":54616354159},{"date":"2025-02-07","current":-74.204707,"twenty":-38.720974,"median":-23.179575,"eighty":13.91548,"marketCap":58296338581},{"date":"2025-02-14","current":-68.942526,"twenty":-39.742666,"median":-23.199597,"eighty":13.854976,"marketCap":54032941995},{"date":"2025-02-21","current":-78.532535,"twenty":-40.936164,"median":-23.213534,"eighty":13.833941,"marketCap":61886567285},{"date":"2025-02-28","current":-83.363188,"twenty":-41.78603,"median":-23.229233,"eighty":13.752998,"marketCap":65476795989},{"date":"2025-03-07","current":-82.972913,"twenty":-43.765472,"median":-23.273351,"eighty":13.720056,"marketCap":65431918130},{"date":"2025-03-14","current":-81.918752,"twenty":-44.36559,"median":-23.404228,"eighty":13.69943,"marketCap":64624116672},{"date":"2025-03-21","current":-77.113549,"twenty":-46.703645,"median":-23.571971,"eighty":13.681934,"marketCap":60809498674},{"date":"2025-03-28","current":-85.082441,"twenty":-50.561624,"median":-23.656456,"eighty":13.67268,"marketCap":66957765329},{"date":"2025-04-03","current":-139.968555,"twenty":-51.651807,"median":-23.75284,"eighty":13.662257,"marketCap":77100161418},{"date":"2025-04-11","current":-135.149196,"twenty":-52.531592,"median":-23.854164,"eighty":13.627238,"marketCap":73779199867},{"date":"2025-04-17","current":-136.201828,"twenty":-53.202931,"median":-23.974596,"eighty":13.597708,"marketCap":74452367749},{"date":"2025-04-25","current":-162.080631,"twenty":-54.264543,"median":-23.982021,"eighty":13.592632,"marketCap":88770184906},{"date":"2025-05-02","current":-143.58439,"twenty":-55.295104,"median":-23.989446,"eighty":13.587555,"marketCap":78807100452},{"date":"2025-05-09","current":-136.980788,"twenty":-56.345373,"median":-23.982021,"eighty":13.592632,"marketCap":75710466095},{"date":"2025-05-16","current":-134.501562,"twenty":-57.376977,"median":-23.982021,"eighty":13.592632,"marketCap":74947527196},{"date":"2025-05-23","current":-133.538341,"twenty":-57.747713,"median":-23.982021,"eighty":13.592632,"marketCap":74633375884},{"date":"2025-05-30","current":-133.993142,"twenty":-58.91872,"median":-23.982021,"eighty":13.592632,"marketCap":75216799748},{"date":"2025-06-06","current":-131.180073,"twenty":-59.359698,"median":-23.982021,"eighty":13.592632,"marketCap":73825558226},{"date":"2025-06-13","current":-152.810216,"twenty":-59.540166,"median":-23.982021,"eighty":13.592632,"marketCap":86032580619},{"date":"2025-06-20","current":-145.842175,"twenty":-59.540166,"median":-23.982021,"eighty":13.592632,"marketCap":81948613568},{"date":"2025-06-27","current":-147.346424,"twenty":-59.773257,"median":-23.989446,"eighty":13.587555,"marketCap":83025703780},{"date":"2025-07-04","current":-184.930979,"twenty":-59.773257,"median":-23.989446,"eighty":13.587555,"marketCap":104208477933},{"date":"2025-07-11","current":-180.493504,"twenty":-59.773257,"median":-23.989446,"eighty":13.587555,"marketCap":101605509923},{"date":"2025-07-18","current":-224.51725,"twenty":-59.773257,"median":-23.989446,"eighty":13.587555,"marketCap":126288827263},{"date":"2025-07-25","current":-237.059172,"twenty":-59.773257,"median":-23.989446,"eighty":13.587555,"marketCap":133828458741},{"date":"2025-08-01","current":-250.051759,"twenty":-59.773257,"median":-23.989446,"eighty":13.587555,"marketCap":140291000008},{"date":"2025-08-05","current":-260.24436,"twenty":-59.773257,"median":-23.989446,"eighty":13.587555,"marketCap":146304753688}],"updateTime":1754500321489}}}